Role of <scp>miRNA</scp> in pathogenesis, diagnosis, and prognosis in hepatocellular carcinoma

Lv, Yi; Sun, Xiujuan

doi:10.1111/cbdd.14352

Cited by 8 publications

(4 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, hepatocarcinogenesis is characterized by abnormalities in key signalling pathways activated by related pathways, accompanied by complex mechanisms such as DNA methylation or the regulation of noncoding RNAs[ 101 , 102 ]. Monitoring abnormal signalling during hepatocarcinogenesis in high-risk populations is helpful for the early detection or diagnosis of HCC (Table 1 ) and can be used for timely treatment of HCC patients.…”

Section: Discussionmentioning

confidence: 99%

Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma

Yao,

Fang,

Xie

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

The prevention and early diagnosis of liver cancer remains a global medical challenge. During the malignant transformation of hepatocytes, a variety of oncogenic cellular signalling molecules, such as novel high mobility group-Box 3, angiopoietin-2, Golgi protein 73, glypican-3, Wnt3a (a signalling molecule in the Wnt/β-catenin pathway), and secretory clusterin, can be expressed and secreted into the blood. These signalling molecules are derived from different signalling pathways and may not only participate in the malignant transformation of hepatocytes but also become early diagnostic indicators of hepatocarcinogenesis or specific targeted molecules for hepatocellular carcinoma therapy. This article reviews recent progress in the study of several signalling molecules as sensitive biomarkers for monitoring hepatocarcinogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma

Yao,

Fang,

Xie

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRNAs) have emerged as valuable biomarkers for the early detection of diseases due to their tissue-specific expression profiles ( Chen et al, 2008 ; Song et al, 2023 ; Lv and Sun, 2024 ). However, the measure of miRNA expression levels may vary across different platforms or protocols, which limits the application of diagnostic models.…”

Section: Introductionmentioning

confidence: 99%

In search of the ratio of miRNA expression as robust biomarkers for constructing stable diagnostic models among multi-center data

Ma,

Zhang,

Ding

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are promising biomarkers for the early detection of disease, and many miRNA-based diagnostic models have been constructed to distinguish patients and healthy individuals. To thoroughly utilize the miRNA-profiling data across different sequencing platforms or multiple centers, the models accounting the batch effects were demanded for the generalization of medical application. We conducted transcription factor (TF)-mediated miRNA–miRNA interaction network analysis and adopted the within-sample expression ratios of miRNA pairs as predictive markers. The ratio of the expression values between each miRNA pair turned out to be stable across multiple data sources. A genetic algorithm-based classifier was constructed to quantify risk scores of the probability of disease and discriminate disease states from normal states in discovery, with a validation dataset for COVID-19, renal cell carcinoma, and lung adenocarcinoma. The predictive models based on the expression ratio of interacting miRNA pairs demonstrated good performances in the discovery and validation datasets, and the classifier may be used accurately for the early detection of disease.

show abstract

“…Several studies have emphasized the altered expression patterns and dysregulation of specific circulating miRNAs in the development, progression and metastasis of HCC, signifying their utility as promising diagnostic biomarkers ( Jin et al, 2019 ; Fang et al, 2022 ; Lv and Sun, 2023 ), but comprehensive and up-to-date evidence-based data is still lacking. In this systematic review and meta-analysis, we aimed to comprehensively evaluate the current state of evidence regarding the diagnostic potential of circulating miRNAs as reliable, non-invasive and clinically applicable biomarkers for the detection of HCC intending to provide an input in addressing the unmet needs in early detection of HCC.…”

Section: Introductionmentioning

confidence: 99%

Circulating microRNAs as promising diagnostic biomarkers for hepatocellular carcinoma: a systematic review and meta-analysis

Alemayehu,

Fasil,

Ebrahim

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: Hepatocellular carcinoma (HCC), the most common type of liver cancer, is a major global health problem, ranking as the third leading cause of cancer-related death worldwide. Early identification and diagnosis of HCC requires the discovery of reliable biomarkers. Therefore, the study aimed to assess the diagnostic accuracy of miRNAs for HCC. The protocol was registered on PROSPERO website with the registration number CRD42023417494.Method: A literature search was conducted in PubMed, Scopus, Embase, Wiley Online Library, and Science Direct databases to identify pertinent articles published between 2018 and 30 July 2023. Stata 17.0 software was employed to determine the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic ratio (DOR), and area under the curve (AUC) for evaluating the accuracy of miRNAs in diagnosing HCC. The assessment of heterogeneity among studies involved the use of the Cochran-Q test and I2 statistic tests. Due to the observed significant heterogeneity, the random-effect model was chosen. Subgroup analysis and meta-regression analysis were also undertaken to explore potential sources contributing to heterogeneity. Deeks’ funnel plot was used to assess publication bias. In addition, Fagan’s nomogram and likelihood ratio scattergram were utilized to assess the clinical validity of miRNAs for HCC.Result: Twenty-four articles were included, involving 1,668 individuals diagnosed with HCC and 1,236 healthy individuals. The findings revealed pooled sensitivity of 0.84 (95% CI: 0.80–0.88), specificity of 0.81 (95% CI: 0.77–0.84), PLR of 4.36 (95% CI: 3.59–5.30), NLR of 0.19 (95% CI: 0.15–0.25), DOR of 22.47 (95% CI: 14.47–32.64), and an AUC of 0.89 (95% CI: 0.86–0.91) for the diagnosis of HCC using miRNAs. Furthermore, results from the subgroup analysis demonstrated that superior diagnostic performance was observed when utilizing plasma miRNAs, a large sample size (≥100), and miRNA panels.Conclusion: Hence, circulating miRNAs demonstrate substantial diagnostic utility for HCC and can serve as effective non-invasive biomarkers for the condition. Additionally, miRNA panels, miRNAs derived from plasma, and miRNAs evaluated in larger sample sizes (≥100) demonstrate enhanced diagnostic efficacy for HCC diagnosis. Nevertheless, a large pool of prospective studies and multi-center research will be required to confirm our findings in the near future.

show abstract

Role of miRNA in pathogenesis, diagnosis, and prognosis in hepatocellular carcinoma

Cited by 8 publications

References 71 publications

Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma

Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma

In search of the ratio of miRNA expression as robust biomarkers for constructing stable diagnostic models among multi-center data

Circulating microRNAs as promising diagnostic biomarkers for hepatocellular carcinoma: a systematic review and meta-analysis

Contact Info

Product

Resources

About